Logo image of KMDA

KAMADA LTD (KMDA) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:KMDA - IL0010941198 - Common Stock

7.09 USD
+0.02 (+0.28%)
Last: 12/24/2025, 7:42:47 PM

KMDA Key Statistics, Chart & Performance

Key Statistics
Market Cap408.95M
Revenue(TTM)174.79M
Net Income(TTM)20.44M
Shares57.68M
Float31.45M
52 Week High9.15
52 Week Low5.54
Yearly DividendN/A
Dividend Yield2.75%
EPS(TTM)0.36
PE19.69
Fwd PE16.42
Earnings (Next)03-03 2026-03-03/bmo
IPO2005-08-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


KMDA short term performance overview.The bars show the price performance of KMDA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

KMDA long term performance overview.The bars show the price performance of KMDA in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of KMDA is 7.09 USD. In the past month the price increased by 4.26%. In the past year, price increased by 19.86%.

KAMADA LTD / KMDA Daily stock chart

KMDA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 24.33 406.30B
AMGN AMGEN INC 15.27 179.83B
GILD GILEAD SCIENCES INC 15.34 155.92B
VRTX VERTEX PHARMACEUTICALS INC 26.67 117.47B
REGN REGENERON PHARMACEUTICALS 17.41 82.37B
ALNY ALNYLAM PHARMACEUTICALS INC 785.67 52.94B
INSM INSMED INC N/A 37.84B
NTRA NATERA INC N/A 32.51B
BIIB BIOGEN INC 10.53 25.87B
UTHR UNITED THERAPEUTICS CORP 19.5 22.16B
INCY INCYTE CORP 15.64 19.72B
EXAS EXACT SCIENCES CORP N/A 19.27B

About KMDA

Company Profile

KMDA logo image Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Company Info

KAMADA LTD

2 Holtzman St., Science Park

Rehovot 7670402 IL

CEO: Amir London

Employees: 374

KMDA Company Website

KMDA Investor Relations

Phone: 97289406472

KAMADA LTD / KMDA FAQ

Can you describe the business of KAMADA LTD?

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.


Can you provide the latest stock price for KAMADA LTD?

The current stock price of KMDA is 7.09 USD. The price increased by 0.28% in the last trading session.


What is the dividend status of KAMADA LTD?

KAMADA LTD (KMDA) has a dividend yield of 2.75%. The yearly dividend amount is currently 0.


What is the ChartMill technical and fundamental rating of KMDA stock?

KMDA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Is KAMADA LTD (KMDA) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KMDA.


Is KAMADA LTD (KMDA) expected to grow?

The Revenue of KAMADA LTD (KMDA) is expected to grow by 12.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


How many employees does KAMADA LTD have?

KAMADA LTD (KMDA) currently has 374 employees.


KMDA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to KMDA. When comparing the yearly performance of all stocks, KMDA is one of the better performing stocks in the market, outperforming 75.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

KMDA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to KMDA. KMDA scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KMDA Financial Highlights

Over the last trailing twelve months KMDA reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 28.57% compared to the year before.


Industry RankSector Rank
PM (TTM) 11.7%
ROA 5.42%
ROE 7.71%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%28.57%
Sales Q2Q%12.63%
EPS 1Y (TTM)28.57%
Revenue 1Y (TTM)10.36%

KMDA Forecast & Estimates

9 analysts have analysed KMDA and the average price target is 15.05 USD. This implies a price increase of 112.2% is expected in the next year compared to the current price of 7.09.

For the next year, analysts expect an EPS growth of 41.23% and a revenue growth 12.48% for KMDA


Analysts
Analysts84.44
Price Target15.05 (112.27%)
EPS Next Y41.23%
Revenue Next Year12.48%

KMDA Ownership

Ownership
Inst Owners11.39%
Ins Owners2.34%
Short Float %0.14%
Short Ratio0.52